AG-120 (ivosidenib) is being evaluated in combination with azacitidine for the treatment of previously untreated acute myeloid leukemia (AML) with an IDH1 mutation. This combination therapy targets a specific patient population that is not suitable for intensive chemotherapy, potentially expanding the market for IDH1 inhibitors in AML treatment. The global AML market is projected to grow significantly, driven by advancements in targeted therapies. Competitive landscape includes other IDH inhibitors and hypomethylating agents, necessitating careful monitoring of clinical outcomes and market positioning. Diligence should focus on the trial's efficacy and safety data, as well as regulatory pathways for approval.